Reaffirming the ethics of compassionate medicine, value-based care, MAiD, and multimodal pain management; Olumuyiwa Bamgbade, Salem Pain Clinic Canada In a compassionate health system, value-based care ensures that patients are not choosing death because they lack support but living with dignity because they are genuinely cared for” — Olumuyiwa Bamgbade SURREY, BC, CANADA, July 12, 2025 / EINPresswire.com / -- As Canada expands access to Medical Assistance in Dying (MAiD) for patients with non-t

A Case for Safer Systems in Value-Based Healthcare Delivery From Airway and Breathing Care Lessons During COVID-19; Olumuyiwa Bamgbade, Salem Pain Clinic Canada In value-based care, even the rarest complications matter because every outcome shapes the value we deliver, and every failure teaches us how to improve” — Olumuyiwa Bamgbade SURREY, BC, CANADA, July 12, 2025 / EINPresswire.com / -- Tracheal intubation and extubation are aerosol-generating medical procedures and have become of greater in

New Delhi: Biosimilars are poised to drive the next wave of growth in the Indian pharmaceutical industry and help the country achieve an ambitious goal of $1 trillion in drug exports by 2030, a senior industry executive told ET. The country's biosimilars market has the potential to exceed $60 billion by 2030, according to Namit Joshi, chairman of Pharmexcil , an authorised export promotion agency under the commerce and industry ministry. That would be about half of the whole pharma exports, whic

Washington: Novartis cannot block drugmaker MSN Pharmaceuticals from launching a generic version of its blockbuster heart-failure drug Entresto before its patent expires late next year, a Delaware federal judge said on Friday. U.S. District Judge Richard Andrews rejected Novartis' argument that MSN's generic would infringe one of its patents and denied its request to block the generic from launching until after the patent expires in November 2026. Novartis told the court in a separate filing on

Mumbai: Undertaking a major strategic realignment exercise, Mumbai-based drugmaker Wockhardt has announced to exit the US generics segment amid mounting losses and will sharpen focus on its innovative portfolio of antibiotics and Insulins. In an intimation to the stock exchange the company said that, “In line with its long-term vision to build a differentiated, innovation-driven enterprise, the company has taken the decision to exit the US generic pharmaceutical segment, to put a deeper focus an

New Delhi: The Pharmaceuticals Export Promotion Council of India on Friday sought a review of a recent circular issued by the Central Drugs Standard Control Organisation, which mandates exclusive online submission of Certificate of Pharmaceutical Product (COPP) applications via the ONDLS portal . While the Council supports digital integration and modernisation of regulatory frameworks, it foresees a major disruption to India's pharmaceutical exports , particularly to Rest of World (RoW) markets,

- Presentations highlight clinically meaningful reductions in BMI in patients with acquired hypothalamic obesity – - Full data from Phase 3 TRANSCEND study underscore potential efficacy of setmelanotide, including with prior use or concomitant use of GLP-1s - BOSTON, July 12, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announc

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on July 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to 17 new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 121,700 shares of its common stock. These inducement RSUs are subject to the terms of Travere’s 2018 Equity Incentive Plan (“2018 Plan”) but were granted outside of the 2018 Plan and were granted as in

BEIJING--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”) today issued the following update to set the record straight regarding the Special Meeting of Shareholders (the “Special Meeting”): The Special Meeting was validly adjourned by SINOVAC Chairman Chiang Li on July 8, 2025, due to pending litigation in Antigua regarding the validity of the shares purportedly issued following an invalid private investment in public equity (“PIPE”) to A

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the primary analysis of the Phase 2 RAMP 201 clinical trial was published online in the Journal of Clinical Oncology (JCO). The data reported in the publication showed that avutometinib plus defactinib demonstrated a confirmed overall response rate (ORR) of 31% in all patients with recurrent low-grade s